) .
M with minimal toxicity. Exemestane, a third generation aromatase inhibitor (AI), has been studied in early as well as metastatic hormone receptor-positive breast cancer. This review analyzes all the aspects of exemestane therapy in breast cancer.
Chemistry
Exemestane is an orally active irreversible steroidal aromatase inactivator. It has very high structural similarity with androstenedione [2, 3] [ Figure 1 ].
Pharmacokinetics
The recommended dosage of exemestane is 25 mg taken orally once daily after a meal which is rapidly absorbed reaching peak plasma concentrations of 17 µg/L within one to two hours. Steady state is reached within seven days. Exemestane is extensively metabolized by cytochrome P450 3A4 and aldoketoreductases. The metabolites are either of lower potency or inactive and are excreted equally in urine and feces. [3] Exemestane has a total clearance of 517L/h and a terminal elimination half-life of 27h. [3, 4] Pharmacodynamics
Mechanism of action
In postmenopausal women, aromatase enzyme is responsible for the final step in estrogen synthesis. Exemestane is initially recognized by the aromatase enzyme as false substrate [ Figure 2 ]. This is then transformed through an NADPH-dependent mechanism, to an intermediate that binds irreversibly to � Shetty, et al.: Exemestane exemestane was 14-29% and clinical efficacy was 36.3%, whereas with megestrol-acetate, it was 30.0%.
[11]
In patients of metastatic disease who have progressed on
Cholesterol
Aromatase Aromatase
Estradiol Estrone
Aldosterone Cortisol acetate. The rate of clinical efficacy was 29% and 30%. These studies provide evidence that exemestane is effective in the treatment of repeatedly pretreated metastatic breast cancer patients. [11, 12] Non selective inhibitors
Selective inhibitors
Second line treatment Androstenedione Testosterone associated with the tumor decreased more during exemestane therapy than during megestrol-acetate treatment. In case of visceral metastases, the objective response rate with Second line exemestane therapy decreases the risk of disease progression and the mortality in metastatic breast cancer by nearly 20%. Furthermore, in a study pain and symptoms tamoxifen, exemestane was equivalent to megesterol acetate in terms of response rate but it was superior to megesterol aromatase, causing suicide inhibition and therefore de novo acetate in median time to progression (20 weeks versus 17 synthesis of aromatase is required for subsequent estrogen weeks) and median survival.
[13]
This is in contrast to other third generation inhibitors e.g., anastrozole and letrozole which are competitive First line treatment inhibitors and hence can be displaced from the binding site.
In a long-term Phase II study comparing exemestane and tamoxifen, the overall response (OR) and clinical benefit (CB) Exemestane, at its clinically used dose of 25 mg/day suppressed rates were 41% and 57% respectively for the exemestane group. aromatase activity by 97%, similar to that shown by anastrozole, But in the tamoxifen group the OR and CB rates were 17% at 1 mg/day dose. [6] In vitro studies have demonstrated a doseand 42% respectively.
[14]
related inhibition of aromatase activity with exemestane but other anti-aromatase agents (e.g., aminoglutethimide, Adjuvant therapy anastrozole and letrozole) caused a paradoxical increase in
The Inter group Exemestane Study (IES) [ Table 1 ] showed aromatase activity under similar conditions. [7] [8] [9] This may in part that exemestane therapy after two to three years of tamoxifen explain the development of resistance with nonsteroidal, Type therapy significantly improved disease-free survival as II agents and the ability of exemestane to induce a response compared with the standard five years of tamoxifen when nonsteroidal agents fail.
[10] treatment. [15, 16] Exemestane -Clinical Application Neo-adjuvant therapy Effect of exemestane on aromatization peripherally, in breast Third line therapy cancer and surrounding normal tissue, studied in 12 In a Phase II study, 80 patients, previously treated with postmenopausal women with untreated large or locally endocrine treatments and/or chemotherapy, received 200 mg/ advanced estrogen receptor-rich tumors, also showed a day exemestane. The response rate was 26%, clinical efficacy promising result [ Table 2 ].
[9]
39% and average period achieving objective response was 52 weeks. A similar study with 25 mg exemestane showed clinical Anastrozole and exemestane have been studied in smaller synthesis. [3, 5] efficacy of 24.3%. In two studies, daily 25 mg exemestane was Phase II uncontrolled trials where the median reduction in administered in relapse following tamoxifen and megestroltumor volume was 75-90% and the percentage of patients able to undergo breast-conserving surgery ranged from 80-88%. [17] Aromatase inhibitors and inactivators should not be used in premenopausal women without concomitant ovarian blockade with gonadotropin releasing hormone analogues as ovarian aromatase escapes inhibition because of stimulation by gonadotropins. [2, 18] 
Safety Profile
Exemestane was generally well tolerated in clinical trials at once daily dosages up to 600 mg. Withdrawal due to adverse � Shetty, et al.: Exemestane Table 3 : LEAP study [21] % Change in HDL-C levels The Greek sub-study of TEAM (Tamoxifen and Exemestane Adjuvant Multicenter) International trial evaluated the effects of either adjuvant exemestane or tamoxifen therapy on the lipid profile in 176 postmenopausal early breast cancer patients. After a study period of one year, exemestane was found to have events occurred in 1.7-8% of patients. [3] a neutral effect on total cholesterol and HDL levels. Unlike tamoxifen's positive effect on LDL levels, exemestane did not At a dosage of 25 mg once daily, adverse events were mainly significantly alter LDL levels. Tamoxifen on the other hand Grade one to two in severity. The most commonly occurring increased triglycerides levels, while exemestane resulted in a adverse events were nausea (8-26%), hot flushes (7.5-24%), beneficial reduction. [23] fatigue (7-12%), increased sweating (4.5-12%) and dizziness (3.4-12%) . Significantly fewer patients receiving exemestane Unlike aminoglutethimide, exemestane does not influence than megestrol experienced moderate to severe weight gain plasma total homocysteine levels.
[24]
(7.6 vs. 17.1%).
[3]
In a randomized trial comparing megestrol acetate with Androgenic events have been reported in some patients exemestane as second-line hormonal treatment for metastatic receiving once daily exemestane 200 mg, but were rarely disease in 366 patients, there was no incidence of reported at the recommended dosage. Symptoms that may thromboembolic events with the use of exemestane. [25] have been androgenic in nature and related to exemestane 25 mg were reported in one study (alopecia two patients, acne Oral clearance of exemestane is reduced in the presence of one, hypertrichosis one). [3] significant hepatic or renal disease. The therapeutic implications of this is considered minor because of its relatively In two independent experiments conducted in female SD rats large safety margin and minor side-effects.
[26]
osteoporosis engendered by castration was completely alleviated by simultaneous administration of exemestane or Safety in case of pregnant women and the pediatric age its principal rat and human metabolite, 17-hydroexemestane group is not yet established but administration of which may be attributed to its androgenic action. [19] exemestane in early stages of pregnancy in rats had shown detrimental effects on the fetus and with difficult labor Clinical studies have shown variable effects of exemestane on process.
[27] Exemestane is marketed for use only in lipid profile. In a nine-week trial in advanced breast cancer postmenopausal women. It is contraindicated in pregnant and a 48-week study in postmenopausal woman with breast or lactating women.
[27]
cancer, exemestane resulted in a significant decrease in both total cholesterol and HDL. Exemestane also decreased the total No dose adjustment is required in the geriatric population.
triglycerides levels in this study. [20] There is no cross-resistance between exemestane and other nonsteroidal AIs. [28] In another European Organization of Research and Treatment of Cancer study, 24 weeks of exemestane therapy had no impact on the lipid profile. [20] The Letrozole, Exemestane and Anastrozole Pharmacodynamics (LEAP) study was conducted in 96 healthy postmenopausal women to assess the pharmacodynamic differences between the three AIs at the 12 th and 24 th week. In the exemestane arm, there was a significant decrease in HDL C levels associated with an increase in the ApoB:ApoA-1 ratio. However, no significant differences in the changes in nonHDL-C concentrations were observed between the treatment arms [21] [ Table 3 ].
In another two-year trial enrolling 147 patients, exemestane was found to drop HDL levels by 6-9% with no major effects on serum lipids, coagulation factors or homocysteine levels.
[22]
Exemestane is currently being evaluated extensively in several studies in postmenopausal women as upfront therapy versus tamoxifen in postmenopausal women with early breast cancer. Efficacy, safety and quality of life (QOL) end points are being evaluated in these studies.
Conclusion
Exemestane has been studied in patients of breast cancer who have progressed on tamoxifen and other hormonal therapy and in patients with early breast cancer after two to three years of initial tamoxifen therapy. In the latter, it is the only aromatase inhibitor to show an improved overall survival than tamoxifen. Emerging evidence from other patient subgroups will throw more light on exemestane's role in the entire spectrum of breast cancer. 
